Analysts Set Inspire Medical Systems, Inc. (NYSE:INSP) PT at $271.29

Inspire Medical Systems, Inc. (NYSE:INSP) has earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $271.29.

Several equities analysts have recently weighed in on INSP shares. Morgan Stanley started coverage on shares of Inspire Medical Systems in a research note on Tuesday, March 19th. They issued an “overweight” rating and a $250.00 target price for the company. Mizuho restated a “buy” rating and issued a $250.00 price objective on shares of Inspire Medical Systems in a research report on Wednesday, March 27th. Stifel Nicolaus restated a “hold” rating and issued a $210.00 price objective on shares of Inspire Medical Systems in a research report on Tuesday, January 2nd. KeyCorp started coverage on shares of Inspire Medical Systems in a research report on Tuesday, February 6th. They issued an “overweight” rating and a $278.00 price objective for the company. Finally, Jefferies Financial Group started coverage on shares of Inspire Medical Systems in a research report on Friday, January 19th. They issued a “buy” rating and a $245.00 price objective for the company.

Insider Buying and Selling at Inspire Medical Systems

In other Inspire Medical Systems news, insider Randy Ban sold 3,060 shares of Inspire Medical Systems stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $182.01, for a total transaction of $556,950.60. Following the completion of the sale, the insider now directly owns 3,029 shares in the company, valued at $551,308.29. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director Jerry C. Griffin sold 554 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $198.05, for a total value of $109,719.70. Following the completion of the sale, the director now directly owns 9,744 shares in the company, valued at approximately $1,929,799.20. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Randy Ban sold 3,060 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $182.01, for a total transaction of $556,950.60. Following the completion of the sale, the insider now owns 3,029 shares of the company’s stock, valued at $551,308.29. The disclosure for this sale can be found here. Insiders sold a total of 76,371 shares of company stock worth $15,664,278 over the last three months. 4.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Inspire Medical Systems

A number of hedge funds have recently made changes to their positions in the business. Commonwealth Equity Services LLC lifted its holdings in shares of Inspire Medical Systems by 0.5% in the 1st quarter. Commonwealth Equity Services LLC now owns 6,774 shares of the company’s stock worth $1,585,000 after acquiring an additional 36 shares during the last quarter. Metropolitan Life Insurance Co NY lifted its holdings in shares of Inspire Medical Systems by 2.3% in the 4th quarter. Metropolitan Life Insurance Co NY now owns 1,734 shares of the company’s stock worth $437,000 after acquiring an additional 39 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Inspire Medical Systems by 3.9% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 1,122 shares of the company’s stock worth $364,000 after acquiring an additional 42 shares during the last quarter. Y Intercept Hong Kong Ltd increased its stake in shares of Inspire Medical Systems by 3.7% in the second quarter. Y Intercept Hong Kong Ltd now owns 1,200 shares of the company’s stock worth $390,000 after buying an additional 43 shares during the period. Finally, Pathstone Family Office LLC increased its stake in shares of Inspire Medical Systems by 2.7% in the third quarter. Pathstone Family Office LLC now owns 2,273 shares of the company’s stock worth $403,000 after buying an additional 59 shares during the period. 94.91% of the stock is currently owned by institutional investors.

Inspire Medical Systems Stock Down 1.0 %

INSP opened at $241.12 on Friday. The company has a market capitalization of $7.31 billion, a price-to-earnings ratio of -325.84 and a beta of 1.37. The firm has a 50-day moving average price of $202.84 and a 200-day moving average price of $183.76. Inspire Medical Systems has a twelve month low of $123.27 and a twelve month high of $330.00.

Inspire Medical Systems (NYSE:INSP) last posted its earnings results on Tuesday, February 6th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.53. The firm had revenue of $192.51 million during the quarter, compared to the consensus estimate of $186.75 million. Inspire Medical Systems had a negative net margin of 3.39% and a negative return on equity of 3.93%. The company’s revenue was up 39.6% on a year-over-year basis. During the same quarter last year, the company earned $0.10 earnings per share. On average, sell-side analysts expect that Inspire Medical Systems will post -0.35 earnings per share for the current fiscal year.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.